Teladoc Health Inc. Common Stock (TDOC)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable advantages, honest accounting, and a price that leaves room for error. Teladoc is a large virtual-care platform, with Integrated Care and BetterHelp, and it reported $2.5B of revenue in fiscal 2025. But the quality is not yet there: it lost $200.3M in fiscal 2025, after losing $1.0B in fiscal 2024 and $220.4M in fiscal 2023. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $606.9M and net income was -$38.9M, or -$0.21 per diluted share. FairStock puts revenue growth at -3.95% and profit growth at -19.13%, and the Lynch category is none because the company has lost money in each of the last four years. The numbers do not demonstrate a moat. Financial health is mixed: trailing free cash flow is $118.1M, a 10.8% FCF yield, and debt-to-equity is 0.79. Yet Altman Z-score is -7.86, ROE is -12.98%, and ROCE is -3.22%. At the 2026-10-13 close of $6.00, FairStock shows P/B 0.83 and EV/EBITDA 6.28; the negative P/E means earnings give no anchor. Book value and cash flow may offer a margin of safety, but only if losses narrow and revenue stabilizes. With beta 2.13, Mr. Market can be violent. I would require evidence of durable positive earnings, not just positive cash flow, before calling this a sound value.

In plain English: Teladoc Health runs virtual doctor visits and online mental health services, including BetterHelp. The business looks weak because it keeps losing money and sales have been slipping. At $6.00 on 2026-10-13, the price looks low compared with its accounting net worth, but the losses make it hard to call it clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer